Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma

BACKGROUND: Atezolizumab plus bevacizumab has been proved to have promising antitumor activity and tolerable safety in patients with unresectable hepatocellular carcinoma (HCC). Hepatic arterial infusion chemotherapy (HAIC) also demonstrated high response rates and favorable survival for patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Xin, Yujing, Cao, Fei, Yang, Hongcai, Zhang, Xinyuan, Chen, Yi, Cao, Xiaojing, Zhou, Xiang, Li, Xiao, Zhou, Jinxue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9388744/
https://www.ncbi.nlm.nih.gov/pubmed/35990634
http://dx.doi.org/10.3389/fimmu.2022.929141

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9388744/
https://www.ncbi.nlm.nih.gov/pubmed/35990634
http://dx.doi.org/10.3389/fimmu.2022.929141

Ejemplares similares